< Zurück zu den aktuellen Neuigkeiten & Events

Veranstaltungen

HGF are Silver Sponsors of LSPN Europe 2025

Oktober 2025

Veranstaltungsdatum: 4. November 2025

HGF is proud to be a Silver Sponsor of LSPN Europe 2025, a leading forum dedicated to helping life sciences innovators protect and leverage their intellectual property across the entire life cycle of innovation.

The event brings together over 150 senior IP professionals and 20+ expert speakers for a full day of high-level discussions, case studies, and networking opportunities, all designed to explore the latest developments in patent management across the life sciences sector.

As part of this year’s programme, Rachel Fetches, Partner & Head of Law at HGF, will be speaking at a strategic panel session entitled “Behind the Scenes of Big Ticket Litigation: Lessons from the Courts.” The session will examine the dynamics behind major recent disputes and settlements, including the Abbott–Dexcom settlement at the start of 2025, and offer insight into how leading life sciences companies are adapting their IP litigation strategies in a changing European enforcement environment.

Key themes include:

  • The UPC’s growing influence on European patent litigation

  • Case study: Strategic drivers behind the Abbott–Dexcom settlement

  • Biosimilar litigation trends and post-UPC defensive strategies

  • mRNA patent enforcement and emerging case law

  • Standard-essential patents (SEPs): FRAND obligations and licensing approaches

  • Choosing between national courts and the UPC system

Balvinder Matharu, Partner & Patent Attorney, Alex Wood, Senior European Patent Attorney, and Amy Shaw, Patent Attorney, will also be attending the event and are looking forward to joining peers and clients to exchange insights on protecting innovation in the life sciences sector.

With its unique mix of in-house, pharma, biotech, and medtech professionals, LSPN Europe 2025 provides an ideal platform to connect with industry leaders, gain fresh perspectives, and engage in meaningful discussions that shape the future of IP strategy in life sciences.

Find out more below.

Aktuelle Neuigkeiten

The Antibody Series #2 Definition via binding strength in antibody claims: when “binds strongly... but only minimally...” becomes a trap of lack of clarity

Introduction Defining an antibody by its binding strength is common practice in patent claims, but it can quickly become a pitfall under Article 84 EPC on clarity. In this second …

Weiterlesen
Event - 7. January 2026

HGF Brand & Design Conference 2026

Join us on 3rd February 2026 for HGF’s Brand & Design Conference, the must attend event for in-house legal teams, brand leaders, creatives, and innovators shaping the future of IP. …

Veranstaltungsdetails

Empowered, Not Replaced: The Risks and Rewards of Using AI Tools in Patent Prosecution

With the rapid rise of AI and extreme hype around generative AI tools in the workplace, patent firms around the world have had to seriously consider to what extent they …

Weiterlesen

EU Agrees on NGT Plant Regulation: What It Means for Patents and Licensing

The European Parliament and Council have reached a provisional agreement for plants developed using New Genomic Techniques (NGTs) – below we summarise the main points and set out the requirements …

Weiterlesen

When Retail Branding Meets Politics

(Inter IKEA Systems v Algemeen Vlaams Belang (Case C‑298/23) In November 2022, the Flemish political party Vlaams Belang presented its “IKEA-PLAN – Immigratie Kan Echt Anders” (“Immigration Really Can Be Different”). …

Weiterlesen

Büro geschlossen – Dezember 2025 / Januar 2026

HGF Büro geschlossen – Dezember 2025 / Januar 2026   UK Donnerstag, 25. und Freitag, 26. Dezember 2025 GESCHLOSSEN Donnerstag, 1. Januar 2026* GESCHLOSSEN * Freitag, 2. Januar 2026 – …

Weiterlesen

Oft kopiert, nie erreicht: Wann werden Alltagsgegenstände zum Gegenstand des Urheberrechts?

Die Grenze zwischen „reinen“ Kunstwerken und bloßen Gebrauchsgegenständen – Können ikonische, aber alltägliche Produkte urheberrechtlich geschützt werden? Die obige Frage wurde vom Generalanwalt in den verbundenen Rechtssachen C‑580/23 und C‑795/23 …

Weiterlesen

T 0883/23: Dosierungsansprüche und ihr Anspruch auf Priorität, wenn in der Prioritätsanmeldung nur das Protokoll der klinischen Studie offengelegt wurde

In einer kürzlich ergangenen Entscheidung der Beschwerdekammer (BoA) des EPA entschied die BoA, dass Ansprüche, die auf eine Kombination von pharmazeutischen Wirkstoffen (APIs) in bestimmten Dosen gerichtet sind, keinen Anspruch …

Weiterlesen